But, while these two compounds might sound similar in name, they couldn't be more different when it comes to the ways in which they support your health
Her personal journey drives Shotsy's development, where the needs of fellow GLP-1 patients are the highest priority
Splitting an 8 mg dose into two 4 mg injections lowers peak concentration without meaningfully reducing the gastrointestinal side-effect burden
withdrawn in 2018), tirzepatide (Mounjaro for type II diabetes and Zepbound for obesity, a dual GIP/GLP1 receptor agonist administered at up to 15 mg once weekly), and semaglutide (Ozempic for type II diabetes at up to 2 mg once weekly, and Wegovy for obesity at 2.4 mg once weekly
TRIUMPH-4: The first positive Phase 3 readout Study design TRIUMPH-4 enrolled 445 adults with obesity or overweight plus knee osteoarthritis, excluding participants with type 2 diabetes